≥99% HPLCPre-filled pen

Teriparatide

Name: Teriparatide
Brand: Dripfy
Availability: InStock

What it is?

Teriparatide is a recombinant form of parathyroid hormone (PTH 1–34) positioned for skeletal-health frameworks where bone formation signalling is the primary endpoint. It is studied and clinically utilised for its anabolic action on bone, supporting protocols that focus on rebuilding bone architecture rather than only slowing loss.

Dripfy Advantage

Osteoblast activation: Stimulates pathways that activate osteoblast function, supporting new bone formation dynamics.
Bone remodelling regulation: Influences bone turnover signalling, shifting remodelling balance toward formation in appropriately structured regimens.
Calcium homeostasis support: Associated with improved calcium utilisation markers, including absorption and retention dynamics.
Structural integrity outcomes: Positions skeletal tissue toward improved microarchitecture markers, supporting overall bone strength endpoints.

Clinical Applications & Therapeutic Potential

Bone mineral density endpoints: Potential increases in bone mineral density (BMD) markers and improved skeletal strength indices.
Fracture-risk reduction: Potential reductions in fracture-risk endpoints through improved bone quality and density measures.
Severe osteoporosis frameworks: Commonly positioned for advanced osteoporosis protocols where anabolic bone-building is required.
True bone-formation profile: Distinct from antiresorptives: positioned to stimulate new bone formation rather than solely preventing loss.

Composition & Formulation

Peptide: Recombinant human parathyroid hormone fragment PTH(1–34)
Format: Ready-to-use pre-filled pen

€406

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Teriparatide

Recombinant parathyroid hormone (PTH 1-34); anabolic osteoporosis medicine · Pre-filled pen

A· Strong evidence

Teriparatide is a recombinant fragment of parathyroid hormone (PTH 1-34) that, when given intermittently, preferentially stimulates osteoblasts to build new bone, shifting bone remodelling toward formation. This anabolic action improves bone microarchitecture and, in trials, reduces the risk of vertebral and non-vertebral fractures. In a longevity context its role is specifically bone health in people with osteoporosis or high fracture risk.

Studied use areas

Osteoporosis with high fracture risk (approved indication)
Bone-formation and bone-density improvement
Bone microarchitecture and skeletal-strength support
Glucocorticoid-induced bone loss (approved context)

Safety & status

Prescription-only medicine in the EU and UK; must be prescribed and monitored by a physician
Contraindicated in certain conditions (e.g. some bone cancers, unexplained high calcium, prior skeletal radiation); assessment is essential
Can cause side effects such as dizziness, leg cramps, nausea and raised blood calcium
Approved for a limited treatment duration under EMA/MHRA labelling

⚕ Clinical note: This is educational information only and not medical advice. Teriparatide is a prescription-only medicine; the decision to use it and any regimen must be individualised and determined by a treating physician.

Evidence: Grade A — approved, prescription-only medicine with randomised controlled trial evidence for reducing fractures in osteoporosis. · References: EMA/MHRA product information for teriparatide; Randomised controlled trials of anabolic osteoporosis therapy; International osteoporosis treatment guidelines